Furthermore, in light of the high‐titer anti‐β2GPI antibodies present in patients with antiphospholipid syndrome (APS), along with oxLDL/β2GPI and β2GPI/anti‐β2GPI complexes, we designated these components as a control group for oxLDL/β2GPI/anti‐β2GPI in this study. This evidence concerns the gene APOH and autoimmune polyendocrinopathy.